← Eichor
Study identifier: NCT06456983 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the MECT-RESIST Trial

Condition: Schizophrenia · Treatment Resistant Schizophrenia  ·  Sponsor: Central Institute of Mental Health, Mannheim

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

Schizophrenia is one of the most severe and costliest mental disorders in terms of human suffering and societal expenditure. About 15-30% of patients do not respond to all known antipsychotics, including clozapine, the current gold-standard in these cases. Hence, a recent Cochrane review stated that the quality of the existing studies is too poor to recommend any intervention in addition to clozapine and that new, randomized controlled trials independent from the pharmaceutical industry need to be performed to substantially improve patient care. Although electroconvulsive therapy (ECT) was initially used to treat schizophrenia, it is nowadays by far underused in the therapy of schizophrenia in many countries. ECT is well known to be highly effective in clozapine-treatment-resistant schizophrenia (CRS), and synergistic effects of clozapine and ECT have been demonstrated. However, relapse rates after successful courses of ECT are still very high, and evidence for maintenance ECT (mECT) in CRS is scarce at best. In a multi-center trial the investigators aim to examine the effectiveness of mECT in treatment-resistant patients with schizophrenia who improved after a course of routine ECT. If mECT will lead to a later timepoint of relapse and/or to a higher proportion of relapse-free patients compared to those undergoing treatment as usual, this trial would have an enormous impact on therapeutic strategies for "treatment-resistant" patients and would induce a profound change of cur…

This description comes directly from the study's public registry record.

Talk to the study team

Alexander Sartorius, Prof  ·  +49-621-1703  ·  alexander.sartorius@zi-mannheim.de

Christian R Wolf, Prof  ·  +49-6221-56  ·  Christian.Wolf@med.uni-heidelberg.de

Always discuss trial participation with your own doctor first.

Locations (14)

Dept. of Psychiatry, RWTU AachenAachen, GermanyNot Yet Recruiting
Dept. of Psychiatry, University of AugsburgAugsburg, GermanyNot Yet Recruiting
Klinik für Psychiatrie, GöppingenGöppingen, GermanyNot Yet Recruiting
Departmet of Psychiatry, University Medical Center GöttingenGöttingen, GermanyNot Yet Recruiting
Dept. of Psychiatry, Hannover Medical SchoolHanover, GermanyNot Yet Recruiting
Universitätsklinikum Heidelberg, Klinik für Allgemeine PsychiatrieHeidelberg, GermanyNot Yet Recruiting
Zentrum für Psychische GesundheitIngolstadt, GermanyNot Yet Recruiting
Dept. of Psychiatry, University MainzMainz, GermanyNot Yet Recruiting
Department of Psychiatry and Psychotherapy, Central Institute of Mental Health (CIMH)Mannheim, GermanyRecruiting
Dept. of Psychiatry, LMU MünchenMünchen, GermanyNot Yet Recruiting
Clinic for Psychiatry, SaarbrückenSaarbrücken, GermanyNot Yet Recruiting
Klinik für Psychiatrie, SiegenSiegen, GermanyNot Yet Recruiting

+ 2 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06456983